Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment

Silo Pharma, a developmental-stage biopharmaceutical company based in Sarasota, Florida, has taken a significant step in its intellectual property strategy by receiving a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead asset, SPC-15. This novel intranasal therapeutic is aimed at preventing or mitigating stress-induced behavioral responses, specifically targeting post-traumatic stress disorder (PTSD).

According to Silo Pharma’s Chief Executive Officer, Eric Weisblum, securing U.S. patent protection for this invention is a critical component of the company’s strategy for SPC-15 as it advances the drug’s development for PTSD.

Silo Pharma’s biopharmaceutical intellectual property portfolio currently holds numerous issued and allowed patents, reflecting the company’s ongoing efforts to expand its intellectual property base. In addition to SPC-15, the company’s pipeline includes SP-26, a therapeutic for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease.

The Notice of Allowance indicates that the patent office has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. This development underscores Silo Pharma’s dedication to advancing its core biopharmaceutical pipeline and expanding its technology platforms.

Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories.

The release also notes that this news contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the company’s technology platforms, retaining and expanding the company’s customer base, fluctuations in consumer spending on the company’s products, and other factors. Accordingly, although the company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.